2024 Clinic Nuclear Medicine Radiation Oncology 
AuntMinnie
OCTOBER 2, 2024
The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. Lindquester, et al, Journal of the American College of Radiology , July 1, 2024. Francisco, et al, Emergency Radiology , April 26, 2024.
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
APRIL 4, 2024
Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging. Theranostics is becoming a treatment option for a larger volume of cancer patients. Hope added.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. The nuclear radiologist, nuclear medicine technologist, and radiation safety team are all present to administer an infusion.
Imaging Technology
JANUARY 8, 2024
GE HealthCare expects to integrate MIM Software solutions into its advanced visualization offerings to facilitate AI-based segmentation and contouring as well as dosimetry analysis for patients across their treatment journeys and in the growing fields of radiology, molecular imaging, and radiation oncology.
Imaging Technology
APRIL 5, 2024
and around the world, with many promising drugs in clinical trials. The Ge-68/Ga-68 generator on the other hand, is an easily transportable, small metal box and can be obtained much more cost-efficient, leading to cost reductions in nuclear medicine clinics and practices while increasing flexibility.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. The nuclear radiologist, nuclear medicine technologist, and radiation safety team are all present to administer an infusion.
Expert insights. Personalized for you.
143 
Let's personalize your content